What follow-up procedure should be communicated to participants who withdraw from a trial?

• A. The follow-up procedure if they stop taking the investigational product or withdraw from the trial
• B. No follow-up is needed after withdrawal
• C. They must continue all study visits even after withdrawal
• D. Data collection continues for 30 days after withdrawal

Answer: (A)

The key idea is that participants must be informed about what safety and data follow-up will look like if they withdraw. When someone stops taking the investigational product or leaves the trial, the sponsor or investigator should clearly communicate the plan for any safety follow-up and data collection after withdrawal. This ensures that potential adverse events or ongoing safety concerns are captured and that the participant knows how they might be contacted for safety information, if applicable.

No follow-up after withdrawal would leave important safety data unknown and data integrity at risk, so that option isn’t appropriate. Requiring all study visits to continue after withdrawal isn’t universally correct, since withdrawal can end the participant’s involvement unless the protocol or consent specifies ongoing follow-up. Data collection continuing for a fixed period (like 30 days) is not a universal rule and depends on the protocol; what matters is that there is a communicated plan for any post-withdrawal safety follow-up.